Cargando…

Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Our objective was to clarify the heterogeneity in response to infliximab treatment in rheumatoid arthritis (RA); to this end, a bioassay was designed to explore the contribution of circulating tumour necrosis factor (TNF)-α bioactivity and its possible link to response. The bioassay is based on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marotte, Hubert, Maslinski, Wlodzimierz, Miossec, Pierre
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064892/ https://www.ncbi.nlm.nih.gov/pubmed/15642135 http://dx.doi.org/10.1186/ar1465

Ejemplares similares

Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, H, et al.
Publicado: (2003)

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
por: Marotte, Hubert, et al.
Publicado: (2008)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Shared epitope and rheumatoid arthritis severity: association with infliximab treatment in a postmarketing study
por: Marotte, H, et al.
Publicado: (2003)

Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients
por: Rinaudo-Gaujous, Mélanie, et al.
Publicado: (2019)

A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
por: Marotte, Hubert, et al.
Publicado: (2007)

IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels
por: Robert, Marie, et al.
Publicado: (2019)

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
por: Wijbrandts, C A, et al.
Publicado: (2008)

Increased AP-1 and NF-κB activation and recruitment with the combination of the proinflammatory cytokines IL-1β, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes
por: Granet, Corinne, et al.
Publicado: (2004)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis
por: Ciechomska, Marzena, et al.
Publicado: (2019)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Cartilage and bone damage in rheumatoid arthritis
por: Ostrowska, Monika, et al.
Publicado: (2018)

Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes
por: Quintin, Emilie, et al.
Publicado: (2010)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
por: Bonek, Krzysztof, et al.
Publicado: (2022)

Interleukin-15 as a Biomarker Candidate of Rheumatoid Arthritis Development
por: Kurowska, Weronika, et al.
Publicado: (2020)

Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
por: Massalska, Magdalena, et al.
Publicado: (2020)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis
por: Kurowska, Weronika, et al.
Publicado: (2017)

Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab
por: Magiera, Michal, et al.
Publicado: (2011)

Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization
por: Assas, B. M., et al.
Publicado: (2016)

IL-17, synoviolin and rheumatoid arthritis chronicity
por: Miossec, Pierre
Publicado: (2012)

Significance of bone marrow edema in pathogenesis of rheumatoid arthritis
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2013)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
por: Bonek, Krzysztof, et al.
Publicado: (2021)

Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis
por: Huang, Qiu-lan, et al.
Publicado: (2017)

Monocyte-related biomarkers of rheumatoid arthritis development in undifferentiated arthritis patients – a pilot study
por: Kurowska, Weronika, et al.
Publicado: (2018)

Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
por: Stranks, Lachlan, et al.
Publicado: (2022)

How does infliximab work in rheumatoid arthritis?
por: Maini, Ravinder N, et al.
Publicado: (2002)

Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis
por: Bonaventura, Paola, et al.
Publicado: (2017)

Role of inflammatory factors and adipose tissue in pathogenesis of rheumatoid arthritis and osteoarthritis. Part I: Rheumatoid adipose tissue
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2013)

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Ciechomska, Marzena, et al.
Publicado: (2018)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’
por: Miossec, Pierre
Publicado: (2014)

Antibodies to Citrullinated Proteins (ACPA) Associate with Markers of Osteoclast Activation and Bone Destruction in the Bone Marrow of Patients with Rheumatoid Arthritis
por: Kurowska, Weronika, et al.
Publicado: (2021)

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis
por: Bonetti, N. R., et al.
Publicado: (2019)

Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis
por: Robert, Marie, et al.
Publicado: (2020)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
por: Mulleman, Denis, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_e00ccb301siscukta6ub27ggta